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Background: Bronchoscopic lung volume reduction (BLVR) can be suggested as an alternative 
for surgical lung volume reduction surgery for severe emphysema patients. This article intends 
to evaluate by systematic review the safety and effectiveness of BLVR using a one-way 
endobronchial valve. 
Methods: A systematic search of electronic databases, including MEDLINE, EMBASE, and 
the Cochrane Library, as well as eight domestic databases up to December 2013, was performed. 
Two reviewers independently screened all references according to selection criteria. The Scottish 
Intercollegiate Guidelines Network criterion was used to assess quality of literature. Data from 
randomized controlled trials were combined and meta-analysis was performed. 
Results: This review included 15 studies. Forced expiratory volume in 1 second (FEV
1
) improved 
in the intervention group compared with the control group (mean difference [MD]=6.71, 95% 
confidence interval [CI]: 3.31–10.11). Six-minute walking distance (MD=15.66, 95% CI: 
1.69–29.64) and cycle workload (MD=4.43, 95% CI: 1.80–7.07) also improved. In addi-
tion, St George’s Respiratory Questionnaire score decreased (MD=4.29, 95% CI: -6.87 to 
-1.71) in the intervention group. In a subgroup analysis of patients with complete fissure, the 
FEV
1
 change from baseline was higher in the BLVR group than in the control group for both 
6 months (MD=15.28, P0.001) and 12 months (MD=17.65, P0.001), whereas for patients 
with incomplete fissure, FEV
1
 and 6-minute walking distance showed no change. One-year 
follow-up randomized controlled trials reported deaths, although the cause of death was not 
related to BLVR. Respiratory failure and pneumothorax incidence rates were relatively higher 
in the BLVR group, but the difference was not significant.
Conclusion: BLVR may be an effective and safe procedure for the treatment of severe COPD 
patients with emphysema, based on existing studies.
Keywords: endobronchial valve, bronchoscopic valve lung volume reduction, systematic 
review, meta-analysis
Introduction
Chronic obstructive pulmonary disease (COPD) is a respiratory disease characterized 
by irreversible abnormal lung inflammation and shows progressive airflow limitation.1 
It is the fifth leading cause of death in high-income countries2 and is one of the major 
public health problems across the world. According to the Global initiative for chronic 
Obstructive Lung Disease (GOLD), it is predicted that COPD will be the third cause 
of death in 2020.3 To reduce hyperinflation, lung volume reduction surgery for severe 
emphysema has been performed for over 30 years. Surgery-related complications and 
mortality are the main concerns with this form of treatment.4
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Bronchoscopic lung volume reduction (BLVR) was 
introduced to maintain the effect of lung volume reduction 
and also reduce surgery-related complications and mortality.5 
Many studies of BLVR have been published, with the 
majority of study designs being case series. Therefore, ran-
domized controlled trials (RCTs) have been recommended 
for evidence enhancement.6 Recently, the US and Europe 
have reported results of multicenter RCTs using unilateral 
bronchial valves for BLVR, but meta-analysis is not yet 
published.7,8 This study is a systematic review to evaluate the 
effectiveness and safety of BLVR using unilateral bronchial 
valves in COPD with emphysema.
Materials and methods
search strategy
A literature search was performed using eight domestic 
research databases, including KoreaMed, and core databases 
such as MEDLINE, EMBASE, and the Cochrane Library up 
to December 2013. Key question and patient intervention 
comparators and outcomes were defined under the advice of 
expert groups. The presearch included 148 article abstracts. 
Extensive searches of databases using the terms “endoscopic 
lung volume reduction”, “bronchoscopic lung volume reduc-
tion”, “endobronchial valve”, and “BLVR” were performed. 
Terms were related to the intervention and modified accord-
ing to each database’s index term, such as Medical Subject 
Heading (MeSH) and EMTREE.
Inclusion/exclusion criteria
Studies that met the following criteria were included: 1) study 
population is people with COPD with severe emphysema; 
2) intervention is BLVR using a unilateral bronchial valve; 
3) study design is an RCT, a cohort study, or a case series; 
4) reported one of the predetermined outcomes; and 
5) published in Korean or English. 
Studies on animal trial or preclinical studies and non-
original articles such as reviews, editorials, letters, and 
comments were excluded. Articles not published in either 
Korean or English and studies with duplicate subjects (study 
using the same outcome indicators published in duplicate) 
were also excluded.
Types of outcome measures
Primary outcome was lung function at forced expiratory 
volume in 1 second (FEV
1
). Secondary outcomes were 
6-minute walk distance (6MWD), cycle workload (Watt), 
quality of life: St George’s Respiratory Questionnaire 
(SGRQ) score, dyspnea scale: modified Medical Research 
Council score, and safety issues: major complications (death, 
pneumothorax, massive hemoptysis) and minor complications 
(pneumonia, minor hemoptysis, COPD exacerbation). 
Data collection and analysis
selection of studies and quality 
assessment
Each stage, from the literature search to the application of 
selection criteria and data extraction, was independently 
undertaken by two researchers. Study selection was carried 
out by predefined inclusion/exclusion criteria. An expert 
group consisting of respiratory medicine and evidence-based 
medicine specialists and thoracic surgery specialists in COPD 
guided each stage. Quality assessment of selected studies 
was carried out using tools of the Scottish Intercollegiate 
Guidelines Network.9
Data extraction and management
According to a preagreed data extraction format, two inves-
tigators independently extracted data for review. Continuous 
variables such as mean change from baseline, median range, 
and standard deviation were converted according to the 
formula in the Cochrane Handbook for Systematic Reviews of 
Interventions.10 The extracted data syntheses were performed 
both quantitatively and qualitatively. 
Measurement and treatment effect
The mean difference (MD) and 95% confidence interval 
(CI) from each individual RCT were calculated, and meta-
analysis using a fixed effect model was performed.11 Two 
RCTs7,8 were included in the meta-analysis. One set of data 
from an RCT12 was not included, because the comparator 
and follow-up period were different. Statistical analysis 
was performed using Cochrane RevMan version 5.2 and 
Comprehensive Meta Analysis software.
Results
study characteristics 
A total of 1,016 studies were retrieved from the database. 
After exclusion of duplicates, 678 studies remained. Finally, 
15 studies were selected according to the selection and exclu-
sion criteria (Figure 1): three RCTs,7,8,12 one cohort study,13 
and eleven case studies.14–24 All studies used a duckbill-type 
endobronchial valve. Six studies used a Zephyr® valve and 
eight studies used an Emphasys® valve (Table 1). 
International Journal of COPD 2015:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
705
Bronchoscopic lung volume reduction on COPD
Identified studies through electronic
searches of databases (total n=1,016)
•  Ovid-MEDLINE (n=329), Ovid-EMBASE (n=633)
•  Cochrane library (n=46)
•  Domestic databases and hand-search (n=8)
Remaining studies after
excluding duplicates (n=678)
Full-text articles assessed
for eligibility (n=232)
Studies included in synthesis
(n=15)
Excluded by selection criteria (n=446)
1.  Animals or pre-clinical studies (n=22)
2.  Not original articles (n=230)
3.  Gray literatures (n=95)
4.  Case reports (n=53)
5.  Did not published in English or Korean (n=46)
1.  Patients did not have COPD with
 emphysema (n=68)
2.  Not performed BLVR intervention (n=123)
3.  Did not report outcomes of our
 interest (n=20)
4.  Patient duplicates as same outcomes (n=6) 
Excluded studies (n=217)
Figure 1 Flow diagram for identification of selected articles.
Abbreviation: BlVr, bronchoscopic lung volume reduction.
Clinical effectiveness
Two RCTs included in the meta-analysis compared the 
intervention group with the control group that performed 
only medical treatment. Each outcome measure, such as 
FEV
1
, 6MWD, cycle workload, and SGRQ, was reported 
(Figure 2). Six months after, the mean change from baseline 
and standard error were calculated for each group. The MDs 
with 95% CI were compared between the intervention group 
and the control group. The FEV
1
 improved in the interven-
tion group compared with the control group (MD=6.71). 
6MWD and cycle workload in the intervention group also 
increased (MD=15.66, MD=4.43). The SGRQ score in the 
intervention group decreased compared with the control 
group (MD=-4.29).
Although not included in the meta-analysis, the other 
RCT12 reported that for BLVR compared with the sham pro-
cedure (bronchoscopy) over 3 months, computed tomography 
(CT) lung volume and number of SGRQ responders were 
increased in the intervention group by 24.2% (8/33) compared 
with the control group (0/33). However, FEV
1
 and 6MWD 
were no different between the two groups. 
One retrospective cohort study13 performed quantitative 
CT image analysis before and after the procedure. After 
6 months of observation of lung volume, target lobe volume 
in the intervention group decreased from baseline (-0.451 cc, 
P0.0001), but not in the control group (-0.0051 cc, 
P=0.70).
Clinical effectiveness according to fissure 
completeness
The subgroup was evaluated for the presence of complete 
fissure, and several outcomes were compared. The results 
are shown in Table 2. For patients with complete fissure, the 
FEV
1
 change from baseline in the BLVR group was higher 
than in the control group for both 6 months (MD=15.29, 
P0.001) and 12 months (MD=17.65, P0.001). However, 
for the patients with incomplete fissure, mean change of FEV
1
 
and 6MWD was not different. 
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In addition, one case series study reported that 5-year 
survival rate of the fissure group was 83.3%, whereas the 
nonfissure group was 24.0% by log-rank test (P=0.0036).21
safety-related outcomes
Three RCTs reported safety:7,8,12 two of them7,8 compared 
BLVR with medical treatment, and the other RCT12 com-
pared BLVR with sham bronchoscopy. Firstly, one of the 
RCTs7 compared BLVR with medical treatment and found 
that mortality over 12 months occurred in 5.4% of the BLVR 
group of 111 participants and in 6.7% of the control group 
of 60 participants, although it was not statistically differ-
ent. An independent committee of the RCT judged that the 
death and the BLVR procedure were not related. Respiratory 
failure occurred only in the intervention group (9.0%). How-
ever, after 12 months, the occurrence of respiratory failure 
was not different between the two groups. The incidence 
of pneumothorax after the procedure occurred only in the 
intervention group (8.2%), yet the incidence of pneumothorax 
was not statistically different. Massive hemoptysis occurred 
only in the intervention group (0.9%).
In the other RCT study,8 death occurred only in the inter-
vention group (2.7%) of 220 participants, although there was 
no significant difference between the two groups (P=0.19). 
Causes of death were three cases of respiratory failure not 
associated with BLVR, one ischemic colitis, one cancer, and 
one massive hemoptysis. Respiratory failure occurred only 
in the intervention group (1.4%). Pneumothorax occurred 
only in the BLVR group (4.1%). One massive hemoptysis 
occurred in the intervention group. There was no statistically 
significant difference between the BLVR group and the 
control group.
One RCT12 compared BLVR with bronchoscopy as a 
sham procedure. During the 3-month follow-up period, 
adverse events were classified according to severity grade: 
serious, severe, moderate, or mild. Serious adverse events 
were seen in the intervention group in 18.9% of 37 partici-
pants and in 11.1% of the control group of 36 participants. 
The incidence rate was not different between the two groups 
(P=0.214). 
Because the follow-up period of RCT studies was less 
than 12 months, ten case series studies were selected for 
safety review. The follow-up observation period ranged from 
1 month up to 5 years. Three of the studies19,21,23 reported 
death, but it was not related to the procedure. Of the major 
complications, seven pneumothorax cases were reported, and 
the incidence rate ranged from 2.5% (2/40) to 23% (3/13). 
Pneumonia distal to valve was 5.2% (1/19) in one study.18T
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1 ∆FEV1
BLVR (one-way valve) Control Mean differenceStudy or subgroup
Author (year)
Author (year)
Author (year)
Author (year)
MeanMean SESE NN
Weight
IV, fixed, 95% CI
Mean difference
IV, fixed, 95% CI
Herth et al (2012)7 7 1.9 111 0.5 2.5 60 31.3% 6.50 (0.42, 12.58)
Sciurba et al (2010)8 4.3 2.5 220 –2.5 2.6 101 68.7% 6.80 (2.70, 10.90)
–100 –50
Favors
(control)
Favors
(BLVR)
0 50 100
–100 –50
Favors
(control)
Favors
(BLVR)
0 50 100
–100 –50
Favors
(control)
Favors
(BLVR)
0 50 100
–100 –50
Favors
(BLVR)
Favors
(control)
0 50 100
Total (95% Cl)
Heterogeneity: χ 2=0.01, df=1 (P=0.94); I 2=0%
Test for overall effect: Z=3.87 (P=0.0001)
331 161 6.71 (3.31, 10.11) 
2 ∆6MWD
BLVR (one-way valve) Control Mean differenceStudy or subgroup
Mean SE NMean SE N
Weight
IV, fixed, 95% Cl
Mean difference
IV, fixed, 95% Cl
Herth et al (2012)7 15 8.6 111 10 10.1 60 28.8% 5.00 (–21.00, 31.00)
Sciurba et al (2010)8 9.3 5 220 –10.7 9.1 101 71.2% 20.00 (3.42, 36.58)
Heterogeneity: χ 2=0.91, df=1 (P=0.34); I 2=0%
Test for overall effect: Z=2.20 (P=0.003)
Total (95% CI) 331 161 15.66 (1.69, 29.64) 
3 ∆Cycle workload
BLVR (one-way valve) Control Mean differenceStudy or subgroup
Mean SE NMean SE N
Weight
IV, fixed, 95% Cl
Mean difference
IV, fixed, 95% Cl
Herth et al (2012)7 2 1.3 111 1.3 60 52.6% 5.00 (1.37, 8.63)–3
Sciurba et al (2010)8 0.6 1.1 220 –3.2 1.6 101 47.4% 3.80 (–0.03, 7.63)
Heterogeneity: χ 2=0.20, df=1 (P=0.66); I 2=0%
Test for overall effect: Z=3.87 (P=0.0010)
Total (95% Cl) 331 161 4.43 (1.80,  7.07) 
4 ∆SGRQ score
Study or subgroup BLVR (one-way valve) Control
Mean SE NMean SE N
Weight Mean difference
Herth et al (2012)7 –5 1.3 111 0 1.7 60 46.8% –5.30 (–9.07, –1.53)
Sciurba et al (2010)8 –2.8 0.9 220 0.6 1.2 101 53.2% –3.40 (–6.94, 0.14)
Heterogeneity: χ 2=0.52, df=1, (P=0.47); I 2=0%
Test for overall effect: Z=3.26 (P=0.001)
Total (95% CI) 331 161 –4.29 (–6.87,  –1.71) 
IV, fixed, 95% Cl
Mean difference
IV, fixed, 95% Cl
Figure 2 Forest plots of effectiveness outcomes – mean change differences from baseline between BlVr group and control group.
Abbreviations: BlVr, bronchoscopic lung volume reduction; ΔFeV1, change in forced expiratory volume in 1 second; se, standard error; IV, independent variable; CI, 
confidence interval; Δ6MWD, change in 6-minute walking distance; ΔCycle workload, change in cycle workload; ΔsgrQ, change in st george’s respiratory Questionnaire.
Discussion
BLVR using a one-way valve is a procedure for COPD 
patients with severe emphysema. Theoretically, a one-way 
valve inserted into the bronchus helps air outflow from the 
target lobe during expiration, and blocks air inflow into 
the lobe during inspiration. This mechanism improves the 
overall lung function and relieves the symptom of dyspnea 
by reducing the lung volume of the target lobe.5 However, 
even after the procedure, there are often collapse failures by 
collateral ventilation, in which case the effect of the proce-
dure is reduced. The known appropriate population for the 
BLVR procedure is heterogeneous emphysema patients, 
and currently two types of bronchial valve are used. One 
is the duckbill-type valve; the other is the umbrella valve.25 
Differences in the structure of these valves may impact on 
efficacy and safety, so only the duckbill-type valve was 
considered in this study.
The UK and European health technology assessment 
reports, based on a synthesis of the literature, did not 
include RCT studies and focused on case studies. For 
evaluation of safety and efficacy related to BLVR, these 
assessments recommended more RCTs.6 In a large RCT 
study, the Endobronchial Valve for Emphysema Pallia-
tion Trial (VENT) was included in the published results. 
VENT’s selection criteria were similar to those for surgi-
cal lung volume reduction.26 Only 6 months of data were 
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available for quantitative synthesis for two of the RCTs 
included in the meta-analysis, so long-term effect could 
not be analyzed. One of the RCT studies compared BLVR 
to sham bronchoscopy, so it was not included in this meta-
analysis.12 This was because both the comparator with VENT 
and the time period were different.12 Based on the result of 
meta-analysis, BLVR is effective in lung function, such as 
FEV
1
, 6MWD, and cycle workload changes, compared with 
the group who maintained medical treatment. In addition, 
SGRQ score significantly decreased in the intervention 
group compared with the control group. One study’s findings 
based on the modified Medical Research Council reported 
significant improvement (P=0.04) between the intervention 
and sham groups. Conversely, during 3-month follow-up of 
other RCTs, compared with a sham procedure, both FEV
1
 
and 6MWD were not different. These results suggest that 
the follow-up period after the procedure may influence its 
effectiveness.12 In one RCT12 and one cohort study,13 in 
chest CT scans, lung volume increased significantly in the 
intervention group. One case series21 followed 40 patients’ 
FEV
1
 and found improvement for up to 5 years. 
A previous study of collateral circulation between 
lobes reported that minimizing interlobar collaterals is the 
important key for success of BLVR intervention.27 As iden-
tified in VENT, the intact fissure (CT phase 90% intact) is 
related to a successful BLVR procedure. When complete fis-
sure between lobes had been confirmed on CT, there was less 
collateral ventilation. This factor then affected the success of 
a treatment BLVR. Identifying this factor can be important to 
target group selection.28 In this study, the meta-analysis result 
shows that the lung function improvement was significant 
in the complete fissure group as opposed to the incomplete 
fissure group. Also in the observational case series, studies 
reported that atelectasis, heterogeneity, and lobe complete-
ness can affect BLVR success.17,28 These results suggest that 
appropriate patient selection and bronchial valve position 
identification are an important area of research, and that an 
evidence-based approach is needed.
In a safety review, VENT7,8 reported deaths in the 
follow-up period of 12 months, but there was no evidence 
directly relating these deaths to the intervention group. 
The incidence rate was not different between interven-
tion group and control group. Complication rates such as 
respiratory failure and pneumothorax incidence rate were 
higher compared with the control group, but most compli-
cations relieved after valve removal or palliative treatment. 
Although only having a short follow-up period of 3 months, 
for the RCT compared with bronchoscopy, the incidence rate 
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of complications was not different between the intervention 
group and the control group.12 Most patients involved in 
these studies had severe emphysema and were considered 
a high-risk population for receiving surgery. Since BLVR 
is a less invasive procedure than surgery, safety could be 
determined as acceptable.
There were no studies that directly compared the effect of 
the BLVR procedure on lung volume reduction as a means to 
examine its safety. However, when considering the severity 
of the patient and ethical issues, direct comparison was 
possible. It can be recommended that indirect comparison or 
long-term observational studies are used to determine safety 
and effectiveness.
Conclusion
Our results suggest that BLVR may be an effective and safe 
procedure for the treatment of severe COPD patients with 
emphysema, based on existing studies. Furthermore, the 
intervention showed lung function improvement in patients 
with complete fissure, whereas patients with incomplete 
fissure showed no response. Therefore, more studies are 
needed to further investigate target patient selection and 
patient safety.
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